Leonard Leads Discussion on Latest Developments in Leukemias and Lymphomas

June 26, 2020
Caroline Seymour
Caroline Seymour

Editor, OncLive®
Caroline Seymour is your initial point of contact for the OncLive® podcast, OncLive On Air™. She joined the company in 2018 as an assistant editor, with expertise in video production and print/digital publication. Email: cseymour@onclive.com

Data in Richter’s transformation, Hodgkin lymphoma, Waldenström macroglobulinemia, and indolent lymphoma were presented at the 2020 ASCO Virtual Scientific Program, and although not entirely practice changing, are deserving of attention.

Data in Richter’s transformation, Hodgkin lymphoma, Waldenström macroglobulinemia, and indolent lymphoma were presented at the 2020 ASCO Virtual Scientific Program, and although not entirely practice changing, are deserving of attention, explained John P. Leonard, MD, Richard T. Silver Distinguished Professor of Hematology and Medical Oncology at Weill Cornell Medicine and New York Presbyterian Hospital, in a virtual presentation during the 2020 ASCO Direct HighlightsTM webcast, a program developed by Physicians’ Education Resource®(PER®), LLC.

Potential for Venetoclax/R-EPOCH in Richter’s Syndrome

Chronic lymphocytic leukemia (CLL) that transforms into an aggressive lymphoma is known as Richter’s syndrome, explained Leonard. These patients have poor outcomes with standard chemoimmunotherapy and novel agents, representing an area of high unmet need.

In 2017, investigators showed that rituximab, etoposide phosphate, prednisone, vincristine, cyclophosphamide, and doxorubicin hydrochloride (R-EPOCH) led to a complete response (CR) rate of 20% in 44 patients.1 The same year, venetoclax (Venclexta) demonstrated an objective response rate (ORR) of 43%, lasting for more than 1 year, suggesting that the addition of the BCL-2 inhibitor could provide additive benefit, said Leonard, who is also a senior associate dean for innovation and initiatives, and executive vice chair, at Weill Cornell Medicine/NewYork-Presbyterian Hospital.2

To that end, investigators evaluated venetoclax plus dose-adjusted R-EPOCH in a multicenter phase 2 trial.3 In the trial, 26 patients received R-EPOCH in the first cycle followed by a 5-day ramp-up of venetoclax to reduce the risk of tumor lysis syndrome, said Leonard. Venetoclax was introduced in cycle 2 at a standing dose of 400 mg daily. Following assessment in cycle 3, patients either continued on the combination or underwent allogeneic hematopoietic stem cell transplant.

Patients had a median age of 63 years (range, 49-77) and received a median of 2 prior treatments for CLL. Poor prognostic features were well represented in the trial, according to the populations’ cytogenetic profile which consisted of del(17p; 26%), TP53 mutations (41%), complex karyotype (44%), NOTCH1 mutations (15%), and IGHV-unmutated disease (48%). Moreover, 56% of patients had bulky adenopathy greater than 5 cm.

Grade 3 or higher hematologic toxicities included neutropenia (grade 3, 58%; grade 4, 54%), anemia (grade 3, 50%), and thrombocytopenia (grade 3, 50%; grade 4, 42%). grade 3 or higher non-hematologic toxicities consisted of febrile neutropenia (grade 3, 26%; grade 4, 12%), hypophosphatemia (grade 3, 23%), hyponatremia (grade 3, 15%), and hyperglycemia (grade 3, 12%; grade 4, 3%).

Six patients received a dose reduction with R-EPOCH, and 4 patients were de-escalated on venetoclax. No patient deaths were reported with the combination.

Among 20 response-evaluable patients, the ORR was 80%, and the CR at the end of treatment was 55%, surpassing historical rates with R-EPOCH alone. A total of 8 patients (47%) went on to transplant, suggesting that the combination provided adequate disease control for patients to proceed to transplant, explained Leonard.

At a median follow-up of 9.3 months, the median progression-free survival (PFS) and overall survival (OS) were both 16.3 months.

“These are some of the better data we’ve seen in Richter’s syndrome and certainly worthy of further evaluation,” said Leonard.

Pembrolizumab Versus Brentuximab Vedotin in Relapsed/Refractory Hodgkin Lymphoma

Both pembrolizumab (Keytruda) and brentuximab vedotin (Adcetris) are approved for patients with relapsed/refractory classical Hodgkin lymphoma. In the phase 3 KEYNOTE-204 trial,4 investigators directly compared the agents in a randomized setting. Eligible patients had relapsed after autologous transplant or were ineligible for transplant and failed 1 prior line of therapy. Patients received 200 mg of intravenous pembrolizumab or 1.8 mg/kg of intravenous brentuximab every 3 weeks for up to 35 cycles.

Patient characteristics were well balanced between arms, said Leonard. Approximately 35% of patients in each arm received prior transplant, and about 40%, 27%, and 32% of patients in each arm had primary refractory disease after frontline therapy or had relapsed within or after 12 months of receiving frontline therapy.

The results showed a median PFS per blinded independent central review of 13.2 months with pembrolizumab versus 8.3 months with brentuximab vedotin, translating to a 45% reduction in the risk of progression or death with the PD-1 inhibitor (HR, 0.65; 95% CI, 0.48-0.88; P = .00271). The 1-year PFS rates were 53.9% and 35.6%, respectively. The PFS benefit also extended to key subgroups, including those who were ineligible for autologous transplant (HR, 0.61), had primary refractory disease (HR, 0.52), and were brentuximab vedotin-naïve (HR, 0.67).

“Pembrolizumab was more effective as a single agent than brentuximab vedotin in this patient population,” said Leonard.

ORRs also favored pembrolizumab, at 65.6% versus 54.2% with brentuximab (HR, 11.3; 95% CI, 0.2-22.1; P = .0225). Additionally, the duration of response was 20.7 months versus 13.8 months, respectively.

The safety profiles were consistent with the known profiles of each agent. All-grade immune-mediated adverse events (AEs), such as hypothyroidism (18.9% vs 2.6%), pneumonitis (10.8% vs 2.6%), and hyperthyroidism (5.4% vs 0.7%) were more common with pembrolizumab, whereas all-grade peripheral sensory neuropathy (13.2% vs 2%), peripheral neuropathy (18.4% vs 2%), nausea (13.2% vs 4.1%), and fatigue (10.5% vs 8.8%) were more common with brentuximab.

“Pembrolizumab should be considered the preferred treatment option and new standard of care for the treatment of relapsed/refractory classical Hodgkin lymphoma in patients that have relapsed after autologous transplant or are ineligible for autologous transplant,” said Leonard.

Comparison of Zanubrutinib Versus Ibrutinib in Waldenström Macroglobulinemia

BTK inhibition is an emerging standard of care in Waldenström macroglobulinemia. While ibrutinib is the sole BTK inhibitor that has an indication in this setting, it is a first-generation inhibitor and is less selective than its next-generation counterpart, zanubrutinib (Brukinsa).

To compare the 2 agents, investigators launched the phase 3 ASPEN trial,5 in which patients in cohort 1 with MYD88-mutant disease were randomized to 160 mg of zanubrutinib daily (n = 102) versus 420 mg of ibrutinib twice daily (n = 99). In cohort 2, patients with wild-type MYD88 disease received zanubrutinib (n = 28). The majority of patients received between 1 to 3 lines of prior therapy.

The CR plus the very good partial response rate or better was comparable in the ibrutinib and zanubrutinib arms, at 19.2% and 28.4%, respectively, failing to meet the primary end point of the trial (P = .0921). Moreover, PFS and OS were relatively similar, though the event-free rates favored zanubrutinib in both respects.

Notably, ibrutinib led to higher rates of death, treatment discontinuations, dose reductions, and dose holds versus zanubrutinib. Among the class effects of BTK inhibitors, zanubrutinib resulted in a lower incidence of grade 3 atrial fibrillation (0% vs 7.1%), diarrhea (3% vs 2%), hemorrhage (5.9% vs 9.2%), hypertension (7.9% vs 15.3%), and infection (18.8% vs 23.5%).

“These results suggest that the newer-generation BTK inhibitor zanubrutinib offers some advantages to ibrutinib in this setting,” said Leonard.

Axicabtagene Ciloleucel in Recurrent Indolent Lymphoma

Having been evaluated and approved in large B-cell lymphoma, it is no surprise that the CD19-directed CAR T-cell therapy axicabtagene-ciloleucel (axi-cel; Yescarta) is being evaluated in patients with indolent non-Hodgkin lymphoma. In the phase 2 ZUMA-5 trial,6 patients with relapsed/refractory follicular lymphoma (n = 125) and marginal zone lymphoma (MZL; n = 25) who had received at least 2 prior lines of therapy received conditioning therapy with fludarabine and cyclophosphamide followed by 2 x 106 CAR T cells/kg.

The majority of patients who underwent leukapheresis (n = 148) also received axi-cel (n = 140) which is not always the case in more aggressive lymphomas where the drop-off rate in CAR T-cell therapy studies can be quite high, said Leonard.

Patients had a median age of 63 years and received a median of 3 prior lines of therapy (range, 2-9). The majority of patients (70%) had refractory disease, and 52% had progressive follicular lymphoma within the first 24 months of treatment.

At a median follow-up of 15.3 months, the ORR was 95% in the follicular lymphoma cohort and 81% in the MZL cohort. The CR rates were 81% and 75%, respectively. A total of 68% of patients in the follicular lymphoma cohort remained in response at the time of data cutoff.

The median PFS was 23.5 months (95% CI, 22.8-NE) in all patients, and the median OS was not reached. Though, the estimated 12-month OS rate was 94.3% (95% CI, 86.8%-97.6%).

Treatment-emergent AEs were consistent with the known safety profile of CAR T-cell therapy, said Leonard. A total of 119 patients (85%) experienced grade 3 or higher AEs, the most common of which included neutropenia (34%), decreased neutrophil count (28%), and anemia (22%).

“How this will fit among the other treatment options for patients with follicular lymphoma remains to be seen,” concluded Leonard.

References:

1. Rogers KA, Huang Y, Ruppert AS, et al. A single-institution retrospective cohort study of first-line R-EPOCH chemoimmunotherapy for Richter syndrome demonstrating complex chronic lymphocytic leukaemia as an adverse prognostic factor. Br J Haematol. 2018;180(2):259-266. doi:10.1111/bjh.15035

2. Davids MS, Roberts AW, Seymour JF, et al. Phase I first-in-human. Study of venetoclax in patients with relapsed or refractory non-Hodgkin lymphoma. J Clin Oncol. 2017;35(8):826-833. doi:10.1200/JCO.2016.70.4320

3. Davids MS, Rogers KA, Tyekucheva S, et al. A multicenter phase 2 study of venetoclax plus dose-adjusted R-EPOCH (VR-EPOCH) for Richter’s syndrome. J Clin Oncol. 2020;38(suppl 15):8004. doi:10.1200/JCO.2020.38.15_suppl.8004

4. Kuruvilla J, Ramchandren R, Santoro A, et al. KEYNOTE-204: Randomized, open-label, phase III study of pembrolizumab (pembro) versus brentuximab vedotin (BV) in relapsed or refractory classic Hodgkin lymphoma (R/R cHL). J Clin Oncol. 2020;38(suppl 15):8005. doi:10.1200/JCO.2020.38.15_suppl.8005

5. Tam C, Opat S, D’Sa S, et al. ASPEN: results of a phase III randomized trial of zanubrutinib versus ibrutinib for patients with Waldenstrom macroglobulinemia (WM). J Clin Oncol. 2020;38(suppl 15):8007. doi:10.1200/JCO.2020.38.15_suppl.8007

6. Jacobson CA, Chavez JC, Sehgal AR, et al. Interim analysis of ZUMA-5: A phase II study of axicabtagene ciloleucel (axi-cel) in patients (pts) with relapsed/refractory indolent non-Hodgkin lymphoma (R/R iNHL). J Clin Oncol. 2020;38(suppl 15):8008. doi:10.1200/JCO.2020.38.15_suppl.8008


x